Skip to main content
Top
Published in: Current Treatment Options in Neurology 8/2020

01-08-2020 | Sarcoidosis | Neurologic Manifestations of Systemic Disease (D Lapides, Section Editor)

Neurologic Manifestations of Systemic Disease: Peripheral Nervous System

Authors: Alex Dworetz, DO, Christina Graley, MD, Hiral Padia, DO, Kelly G. Gwathmey, MD

Published in: Current Treatment Options in Neurology | Issue 8/2020

Login to get access

Abstract

Purpose of Review

The impact that systemic disease has on the peripheral nervous system is vast. Polyneuropathies due to these disorders fall into broad categories including metabolic diseases, nutritional deficiencies, rheumatological diseases, infectious diseases, and malignancy-associated disorders. This review focuses on the treatment of these systemic disease–associated polyneuropathies.

Recent Findings

Many of the specific polyneuropathies covered in this review are relatively rare and understudied. As such treatment recommendations are based on expert opinion, small case series, and case reports. Even more prevalent polyneuropathies, such as diabetes-associated, will be covered, though these too often lack standard treatment approaches. The immune checkpoint inhibitor–associated polyneuropathies have garnered much attention recently. Current treatment recommendations for these polyneuropathies will be discussed.

Summary

Recognition of polyneuropathies associated with the systemic disease is imperative as these acquired polyneuropathies represent potentially treatable disorders. In many circumstances, prompt identification and early treatment prevent permanent neurological deficits and pain. The reader is encouraged to consider these polyneuropathy etiologies in order to expedite diagnostic evaluation and if possible therapeutic intervention.
Literature
2.
go back to reference Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management [Internet]. Diabetes. Metab. Res. Rev. 2011 [cited 2020 Mar 16]. p. 629–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21695762. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management [Internet]. Diabetes. Metab. Res. Rev. 2011 [cited 2020 Mar 16]. p. 629–38. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21695762.
4.
6.
go back to reference Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med [Internet]. 1993;329:977–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8366922. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med [Internet]. 1993;329:977–86. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8366922.
7.
go back to reference Hernández-ojeda J, Román-pintos LM, Rodríguez AD, Cardona- EG, Guillermina A. Effect of rosuvastatin on diabetic polyneuropathy: phase IIa study. Diabetes, Metab Syndr Obes Targets Ther. Dove Medical Press Ltd. 2014;7:401–7. Hernández-ojeda J, Román-pintos LM, Rodríguez AD, Cardona- EG, Guillermina A. Effect of rosuvastatin on diabetic polyneuropathy: phase IIa study. Diabetes, Metab Syndr Obes Targets Ther. Dove Medical Press Ltd. 2014;7:401–7.
8.
go back to reference Fried LF, Forrest KYZ, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complicat. 2001;15:113–9.CrossRef Fried LF, Forrest KYZ, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complicat. 2001;15:113–9.CrossRef
10.
go back to reference Kluding PM, Singleton JR, Pasnoor M, Dimachkie MM, Barohn RJ, Smith AG, et al. Activity for diabetic polyneuropathy (ADAPT): study design and protocol for a 2-site randomized controlled trial. Phys Ther [Internet]. Oxford University Press (OUP); 2016 [cited 2020 Mar 16];97:20–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27417167. Kluding PM, Singleton JR, Pasnoor M, Dimachkie MM, Barohn RJ, Smith AG, et al. Activity for diabetic polyneuropathy (ADAPT): study design and protocol for a 2-site randomized controlled trial. Phys Ther [Internet]. Oxford University Press (OUP); 2016 [cited 2020 Mar 16];97:20–31. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27417167.
12.
go back to reference Maiya RP, Messing RO. Peripheral systems: neuropathy. Handb Clin Neurol. Elsevier B.V.; 2014. p. 513–25. Maiya RP, Messing RO. Peripheral systems: neuropathy. Handb Clin Neurol. Elsevier B.V.; 2014. p. 513–25.
13.
go back to reference Shible AA, Ramadurai D, Gergen D, Reynolds PM. Dry beriberi due to thiamine deficiency associated with peripheral neuropathy and Wernicke’s encephalopathy mimicking Guillain-Barré syndrome: a case report and review of the literature. Am J Case Rep [Internet]. 2019 [cited 2019 Mar 23];20:330–4. Available from: https://www.amjcaserep.com/abstract/index/idArt/914051 Shible AA, Ramadurai D, Gergen D, Reynolds PM. Dry beriberi due to thiamine deficiency associated with peripheral neuropathy and Wernicke’s encephalopathy mimicking Guillain-Barré syndrome: a case report and review of the literature. Am J Case Rep [Internet]. 2019 [cited 2019 Mar 23];20:330–4. Available from: https://​www.​amjcaserep.​com/​abstract/​index/​idArt/​914051
18.
24.
go back to reference Devalia V, Hamilton MS, Molloy AM, British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol [Internet]. 2014 [cited 2019 Mar 23];166:496–513. Available from: https://doi.org/10.1111/bjh.12959 Devalia V, Hamilton MS, Molloy AM, British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol [Internet]. 2014 [cited 2019 Mar 23];166:496–513. Available from: https://​doi.​org/​10.​1111/​bjh.​12959
25.
go back to reference Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. Am Fam Physician. 2017;96:384–9.PubMed Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. Am Fam Physician. 2017;96:384–9.PubMed
28.
go back to reference Chhetri SK, Mills RJ, Shaunak S, Emsley HCA. Copper deficiency. BMJ Publishing Group. 2014;348. Chhetri SK, Mills RJ, Shaunak S, Emsley HCA. Copper deficiency. BMJ Publishing Group. 2014;348.
29.
go back to reference Taylor SW, Laughlin RS, Kumar N, Goodman B, Klein CJ, Dyck PJ, et al. Clinical, physiological and pathological characterisation of the sensory predominant peripheral neuropathy in copper deficiency. J Neurol Neurosurg Psychiatry [Internet]. 2017 [cited 2019 Mar 23];88:839–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28780535. Taylor SW, Laughlin RS, Kumar N, Goodman B, Klein CJ, Dyck PJ, et al. Clinical, physiological and pathological characterisation of the sensory predominant peripheral neuropathy in copper deficiency. J Neurol Neurosurg Psychiatry [Internet]. 2017 [cited 2019 Mar 23];88:839–45. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28780535.
33.
go back to reference Marra CM, Boutin P, Collier AC. Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. Neurology. Lippincott Williams and Wilkins; 1998;51:1678–1681. Marra CM, Boutin P, Collier AC. Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. Neurology. Lippincott Williams and Wilkins; 1998;51:1678–1681.
37.
go back to reference Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals. Risk factors, incidence and management. Drug Saf. 1998:481–94. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals. Risk factors, incidence and management. Drug Saf. 1998:481–94.
41.
go back to reference Leonhard SE, Lant S, Jacobs BC, Wilder-Smith A, Ferreira MLB, Solomon T, et al. Zika virus infection in the returning traveller: what every neurologist should know. Pract Neurol BMJ Publishing Group. 2018;18:271–7.CrossRef Leonhard SE, Lant S, Jacobs BC, Wilder-Smith A, Ferreira MLB, Solomon T, et al. Zika virus infection in the returning traveller: what every neurologist should know. Pract Neurol BMJ Publishing Group. 2018;18:271–7.CrossRef
42.
go back to reference Medina MT, England JD, Lorenzana I, Medina-Montoya M, Alvarado D, De Bastos M, et al. Zika virus associated with sensory polyneuropathy. J Neurol Sci Elsevier B.V. 2016:271–2. Medina MT, England JD, Lorenzana I, Medina-Montoya M, Alvarado D, De Bastos M, et al. Zika virus associated with sensory polyneuropathy. J Neurol Sci Elsevier B.V. 2016:271–2.
43.
go back to reference Arias A, Torres-Tobar L, Hernández G, Paipilla D, Palacios E, Torres Y, et al. Guillain-Barré syndrome in patients with a recent history of Zika in Cúcuta, Colombia: a descriptive case series of 19 patients from December 2015 to March 2016. J Crit Care [Internet]. W.B. Saunders; 2017 [cited 2020 Mar 20];37:19–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27610587. Arias A, Torres-Tobar L, Hernández G, Paipilla D, Palacios E, Torres Y, et al. Guillain-Barré syndrome in patients with a recent history of Zika in Cúcuta, Colombia: a descriptive case series of 19 patients from December 2015 to March 2016. J Crit Care [Internet]. W.B. Saunders; 2017 [cited 2020 Mar 20];37:19–23. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27610587.
44.
go back to reference Smith DE, Beckham JD, Tyler KL, Pastula DM. Zika virus disease for neurologists. Neurol. Clin. Pract. Lippincott Williams and Wilkins. 2016:515–22. Smith DE, Beckham JD, Tyler KL, Pastula DM. Zika virus disease for neurologists. Neurol. Clin. Pract. Lippincott Williams and Wilkins. 2016:515–22.
45.
go back to reference Abrams RPM, Solis J, Nath A. Therapeutic approaches for Zika virus infection of the nervous system. Neurotherapeutics Springer New York LLC. 2017;14:1027–48. Abrams RPM, Solis J, Nath A. Therapeutic approaches for Zika virus infection of the nervous system. Neurotherapeutics Springer New York LLC. 2017;14:1027–48.
46.
go back to reference Wormser GP, Strle F, Shapiro ED, Dattwyler RJ, Auwaerter PG. A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease. Diagn. Microbiol. Infect. Dis. Elsevier Inc.; 2017. p. 163–167. Wormser GP, Strle F, Shapiro ED, Dattwyler RJ, Auwaerter PG. A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease. Diagn. Microbiol. Infect. Dis. Elsevier Inc.; 2017. p. 163–167.
47.
go back to reference Halperin JJ, Shapiro ED, Logigian E, Belman AL, Dotevall L, Wormser GP, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology [Internet]. Lippincott Williams and Wilkins; 2007 [cited 2020 Mar 20];69:91–102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17522387. Halperin JJ, Shapiro ED, Logigian E, Belman AL, Dotevall L, Wormser GP, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology [Internet]. Lippincott Williams and Wilkins; 2007 [cited 2020 Mar 20];69:91–102. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​17522387.
49.
go back to reference Shimoni Z, Bin H, Bulvik S, Niven M, Hazzan R, Mendelson E, et al. The clinical response of West Nile virus neuroinvasive disease to intravenous immunoglobulin therapy. Clin Pract [Internet]. PAGEPress Publications; 2012 [cited 2020 Mar 23];2:18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24765417. Shimoni Z, Bin H, Bulvik S, Niven M, Hazzan R, Mendelson E, et al. The clinical response of West Nile virus neuroinvasive disease to intravenous immunoglobulin therapy. Clin Pract [Internet]. PAGEPress Publications; 2012 [cited 2020 Mar 23];2:18. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​24765417.
50.
go back to reference Slonchak A, Clarke B, MacKenzie J, Amarilla AA, Setoh YX, Khromykh AA. West Nile virus infection and interferon alpha treatment alter the spectrum and the levels of coding and noncoding host RNAs secreted in extracellular vesicles. BMC Genomics [Internet]. BioMed Central Ltd.; 2019 [cited 2020 Mar 23];20:474. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31182021. Slonchak A, Clarke B, MacKenzie J, Amarilla AA, Setoh YX, Khromykh AA. West Nile virus infection and interferon alpha treatment alter the spectrum and the levels of coding and noncoding host RNAs secreted in extracellular vesicles. BMC Genomics [Internet]. BioMed Central Ltd.; 2019 [cited 2020 Mar 23];20:474. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​31182021.
52.
go back to reference Sadeghiyan Galeshkalami N, Abdollahi M, Najafi R, Baeeri M, Jamshidzade A, Falak R, et al. Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis. Life Sci [Internet]. 2019;216:101–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30393023. Sadeghiyan Galeshkalami N, Abdollahi M, Najafi R, Baeeri M, Jamshidzade A, Falak R, et al. Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis. Life Sci [Internet]. 2019;216:101–10. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​30393023.
53.
go back to reference Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med [Internet]. 1988 [cited 2020 Mar 29];319:542–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3136330. Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med [Internet]. 1988 [cited 2020 Mar 29];319:542–8. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​3136330.
55.
go back to reference Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004:1458–86. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004:1458–86.
57.
58.
go back to reference Trippe BS, Barrentine LW, Curole M V, Tipa E. Nutritional management of patients with diabetic peripheral neuropathy with L-methylfolate-methylcobalamin-pyridoxal-5-phosphate: results of a real-world patient experience trial. Curr Med Res Opin [Internet]. Taylor and Francis Ltd; 2016 [cited 2020 Mar 16];32:219–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26439233. Trippe BS, Barrentine LW, Curole M V, Tipa E. Nutritional management of patients with diabetic peripheral neuropathy with L-methylfolate-methylcobalamin-pyridoxal-5-phosphate: results of a real-world patient experience trial. Curr Med Res Opin [Internet]. Taylor and Francis Ltd; 2016 [cited 2020 Mar 16];32:219–27. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26439233.
59.
go back to reference Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116:600–5.CrossRef Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116:600–5.CrossRef
61.
go back to reference Ghadiri-Anari A, Mozafari Z, Gholami S, Khodaei S-A, Aboutorabi-Zarchi M, Sepehri F, et al. Dose vitamin D supplementations improve peripheral diabetic neuropathy? A before-after clinical trial. Diabetes Metab Syndr [Internet]. Elsevier Ltd; 2019 [cited 2020 Mar 16];13:890–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30641826. Ghadiri-Anari A, Mozafari Z, Gholami S, Khodaei S-A, Aboutorabi-Zarchi M, Sepehri F, et al. Dose vitamin D supplementations improve peripheral diabetic neuropathy? A before-after clinical trial. Diabetes Metab Syndr [Internet]. Elsevier Ltd; 2019 [cited 2020 Mar 16];13:890–3. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​30641826.
62.
go back to reference Chen H-T, Lin H-D, Won JGS, Lee C-H, Wu S-C, Lin J-D, et al. Cardiovascular autonomic neuropathy, autonomic symptoms and diabetic complications in 674 type 2 diabetes. Diabetes Res Clin Pract [Internet]. 2008 [cited 2020 Mar 30];82:282–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18824270. Chen H-T, Lin H-D, Won JGS, Lee C-H, Wu S-C, Lin J-D, et al. Cardiovascular autonomic neuropathy, autonomic symptoms and diabetic complications in 674 type 2 diabetes. Diabetes Res Clin Pract [Internet]. 2008 [cited 2020 Mar 30];82:282–90. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18824270.
63.
go back to reference Shehab D, Al-Jarallah K, Abdella N, Mojiminiyi OA, Al Mohamedy H. Prospective evaluation of the effect of short-term oral vitamin D supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract [Internet]. S. Karger AG; 2015 [cited 2020 Mar 30];24:250–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25720672. Shehab D, Al-Jarallah K, Abdella N, Mojiminiyi OA, Al Mohamedy H. Prospective evaluation of the effect of short-term oral vitamin D supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract [Internet]. S. Karger AG; 2015 [cited 2020 Mar 30];24:250–6. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25720672.
64.
go back to reference Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet (London, England) [Internet]. 352:1978–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9872248. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet (London, England) [Internet]. 352:1978–81. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​9872248.
65.
go back to reference Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. Recombinant human nerve growth factor in the treatments of diabetic polyneuropathy. Neurology Lippincott Williams and Wilkins. 1998;51:695–702. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. Recombinant human nerve growth factor in the treatments of diabetic polyneuropathy. Neurology Lippincott Williams and Wilkins. 1998;51:695–702.
66.
go back to reference Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med [Internet]. Blackwell Publishing Inc.; 2015 [cited 2020 Mar 30];16:1163–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25594611. Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med [Internet]. Blackwell Publishing Inc.; 2015 [cited 2020 Mar 30];16:1163–76. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25594611.
68.
go back to reference Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson C-G, Kirk RI, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med [Internet]. 2015;20:658–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25387363. Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson C-G, Kirk RI, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med [Internet]. 2015;20:658–66. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25387363.
69.
go back to reference Lupachyk S, Shevalye H, Maksimchyk Y, Drel VR, Obrosova IG. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic Biol Med [Internet]. 2011 [cited 2020 Mar 30];50:1400–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21300148. Lupachyk S, Shevalye H, Maksimchyk Y, Drel VR, Obrosova IG. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic Biol Med [Internet]. 2011 [cited 2020 Mar 30];50:1400–9. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21300148.
70.
go back to reference Byun YS, Kang B, Yoo YS, Joo CK. Poly (ADP-ribose) polymerase inhibition improves corneal epithelial innervation and wound healing in diabetic rats. Investig Ophthalmol Vis Sci [Internet]. Association for Research in Vision and Ophthalmology Inc.; 2015 [cited 2020 Mar 30];56:1948–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25711635. Byun YS, Kang B, Yoo YS, Joo CK. Poly (ADP-ribose) polymerase inhibition improves corneal epithelial innervation and wound healing in diabetic rats. Investig Ophthalmol Vis Sci [Internet]. Association for Research in Vision and Ophthalmology Inc.; 2015 [cited 2020 Mar 30];56:1948–55. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25711635.
71.
72.
73.
go back to reference Price SA, Agthong S, Middlemas AB, Tomlinson DR. Mitogen-activated protein kinase p38 mediates reduced nerve conduction in experimental diabetic neuropathy: Interactions with aldose reductase. Diabetes [Internet]. 2004 [cited 2020 Mar 30];53:1851–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15220210. Price SA, Agthong S, Middlemas AB, Tomlinson DR. Mitogen-activated protein kinase p38 mediates reduced nerve conduction in experimental diabetic neuropathy: Interactions with aldose reductase. Diabetes [Internet]. 2004 [cited 2020 Mar 30];53:1851–6. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15220210.
74.
76.
go back to reference Andriambeloson E, Baillet C, Vitte PA, Garotta G, Dreano M, Callizot N. Interleukin-6 attenuates the development of experimental diabetes-related neuropathy. Neuropathology. 2006;26:32–42.CrossRef Andriambeloson E, Baillet C, Vitte PA, Garotta G, Dreano M, Callizot N. Interleukin-6 attenuates the development of experimental diabetes-related neuropathy. Neuropathology. 2006;26:32–42.CrossRef
78.
go back to reference Obrosova IG, Stavniichuk R, Drel VR, Shevalye H, Vareniuk I, Nadler JL, et al. Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies. Am J Pathol [Internet]. Elsevier Inc.; 2010 [cited 2020 Mar 30];177:1436–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20724598. Obrosova IG, Stavniichuk R, Drel VR, Shevalye H, Vareniuk I, Nadler JL, et al. Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies. Am J Pathol [Internet]. Elsevier Inc.; 2010 [cited 2020 Mar 30];177:1436–47. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20724598.
79.
82.
85.
go back to reference Kaur M, Singh A, Kumar B, Singh SK, Bhatia A, Gulati M, et al. Protective effect of co-administration of curcumin and sildenafil in alcohol induced neuropathy in rats. Eur J Pharmacol [Internet]. Elsevier B.V.; 2017 [cited 2020 Mar 16];805:58–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28315678. Kaur M, Singh A, Kumar B, Singh SK, Bhatia A, Gulati M, et al. Protective effect of co-administration of curcumin and sildenafil in alcohol induced neuropathy in rats. Eur J Pharmacol [Internet]. Elsevier B.V.; 2017 [cited 2020 Mar 16];805:58–66. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28315678.
86.
88.
go back to reference • Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol [Internet]. 2020 [cited 2020 Mar 875 16];87(5):659–669. Available from: https://doi.org/10.1002/ana.25708. This review highlights the spectrum of immune-related adverse events associated with immune checkpoint inhibitors. This paper also describes a treatment approach for these adverse events. Our understanding of these disorders is rapidly evolving. • Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol [Internet]. 2020 [cited 2020 Mar 875 16];87(5):659–669. Available from: https://​doi.​org/​10.​1002/​ana.​25708. This review highlights the spectrum of immune-related adverse events associated with immune checkpoint inhibitors. This paper also describes a treatment approach for these adverse events. Our understanding of these disorders is rapidly evolving.
89.
91.
go back to reference Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment. J Immunother [Internet]. Lippincott Williams and Wilkins; 2017 [cited 2020 Mar 16];40:221–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28498142. Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment. J Immunother [Internet]. Lippincott Williams and Wilkins; 2017 [cited 2020 Mar 16];40:221–3. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28498142.
92.
go back to reference Sepúlveda M, Martinez-Hernandez E, Gaba L, Victoria I, Sola-Valls N, Falgàs N, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle and Nerve [Internet]. John Wiley and Sons Inc.; 2017 [cited 2020 Mar 16];56:E162–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28439919. Sepúlveda M, Martinez-Hernandez E, Gaba L, Victoria I, Sola-Valls N, Falgàs N, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle and Nerve [Internet]. John Wiley and Sons Inc.; 2017 [cited 2020 Mar 16];56:E162–7. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28439919.
94.
go back to reference Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol [Internet]. 2016 [cited 2020 Mar 16];46:86–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26491202. Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol [Internet]. 2016 [cited 2020 Mar 16];46:86–8. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26491202.
95.
go back to reference Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology [Internet]. Lippincott Williams and Wilkins; 2017 [cited 2020 Mar 16];89:1127–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28821685. Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology [Internet]. Lippincott Williams and Wilkins; 2017 [cited 2020 Mar 16];89:1127–34. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28821685.
96.
go back to reference Möhn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook. J Clin Med [Internet]. MDPI AG; 2019 [cited 2020 Mar 16];8:1777. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31653079. Möhn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook. J Clin Med [Internet]. MDPI AG; 2019 [cited 2020 Mar 16];8:1777. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​31653079.
99.
go back to reference Spain L, Walls G, Messiou C, Turajlic S, Gore M, Larkin J. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer Immunol Immunother [Internet]. Springer Science and Business Media Deutschland GmbH; 2017 [cited 2020 Mar 16];66:113–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27838762. Spain L, Walls G, Messiou C, Turajlic S, Gore M, Larkin J. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer Immunol Immunother [Internet]. Springer Science and Business Media Deutschland GmbH; 2017 [cited 2020 Mar 16];66:113–7. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27838762.
100.
go back to reference Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer [Internet]. BioMed Central Ltd.; 2019 [cited 2020 Mar 16];7:134. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31118078. Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer [Internet]. BioMed Central Ltd.; 2019 [cited 2020 Mar 16];7:134. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​31118078.
101.
103.
go back to reference Alhammad RM, Dronca RS, Kottschade LA, Turner HJ, Staff NP, Mauermann ML, et al. Brachial plexus neuritis associated with anti-programmed cell death-1 antibodies: report of 2 cases. Mayo Clin proceedings Innov Qual outcomes [Internet]. Elsevier BV; 2017 [cited 2020 Mar 16];1:192–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30225416. Alhammad RM, Dronca RS, Kottschade LA, Turner HJ, Staff NP, Mauermann ML, et al. Brachial plexus neuritis associated with anti-programmed cell death-1 antibodies: report of 2 cases. Mayo Clin proceedings Innov Qual outcomes [Internet]. Elsevier BV; 2017 [cited 2020 Mar 16];1:192–7. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​30225416.
105.
go back to reference Johansen A, Christensen SJ, Scheie D, Højgaard JLS, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review [Internet]. Neurology. Lippincott Williams and Wilkins; 2019 [cited 2020 Mar 16]. p. 663–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30850443. Johansen A, Christensen SJ, Scheie D, Højgaard JLS, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review [Internet]. Neurology. Lippincott Williams and Wilkins; 2019 [cited 2020 Mar 16]. p. 663–74. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​30850443.
106.
go back to reference Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer [Internet]. BioMed Central Ltd.; 2019 [cited 2020 Mar 16];7:319. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31753014. Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer [Internet]. BioMed Central Ltd.; 2019 [cited 2020 Mar 16];7:319. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​31753014.
107.
go back to reference Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother cancer [Internet]. BioMed Central Ltd.; 2017 [cited 2020 Mar 16];5:95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29162153. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother cancer [Internet]. BioMed Central Ltd.; 2017 [cited 2020 Mar 16];5:95. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​29162153.
113.
go back to reference Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy–associated peripheral neuropathy: diagnosis and management. Mayo Clin. Proc. Elsevier Ltd; 2017. p. 838–850. Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy–associated peripheral neuropathy: diagnosis and management. Mayo Clin. Proc. Elsevier Ltd; 2017. p. 838–850.
114.
go back to reference •• Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang C-C, Ueda M, Kristen A V, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med [Internet]. 2018;379:11–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29972753. This phase 3 study demonstrates the benefit of patisiran, an RNA interference agent, in the treatment of transthyretin familial amyloidosis polyneuropathy, a previously untreatable disease. •• Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang C-C, Ueda M, Kristen A V, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med [Internet]. 2018;379:11–21. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​29972753. This phase 3 study demonstrates the benefit of patisiran, an RNA interference agent, in the treatment of transthyretin familial amyloidosis polyneuropathy, a previously untreatable disease.
116.
go back to reference •• Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med [Internet]. 2018;379:22–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29972757. This phase 3 study demonstrates the benefit of inotersen, an antisense oligonucleotide, in the treatment of transthyretin familial amyloidosis polyneuropathy, a previously untreatable disease. •• Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med [Internet]. 2018;379:22–31. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​29972757. This phase 3 study demonstrates the benefit of inotersen, an antisense oligonucleotide, in the treatment of transthyretin familial amyloidosis polyneuropathy, a previously untreatable disease.
117.
go back to reference Gemignani F, Marbini A, Pavesi G, Di Vittorio S, Manganelli P, Cenacchi G, et al. Peripheral neuropathy associated with primary Sjögren’s syndrome. J Neurol Neurosurg Psychiatry [Internet]. BMJ Publishing Group; 1994 [cited 2020 Mar 16];57:983–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8057125. Gemignani F, Marbini A, Pavesi G, Di Vittorio S, Manganelli P, Cenacchi G, et al. Peripheral neuropathy associated with primary Sjögren’s syndrome. J Neurol Neurosurg Psychiatry [Internet]. BMJ Publishing Group; 1994 [cited 2020 Mar 16];57:983–6. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8057125.
118.
go back to reference Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, van den Meiracker AH, Vecht CJ, van der Heijde GL, et al. Involvement of the peripheral nervous system in primary Sjögren’s syndrome. Ann Rheum Dis [Internet]. 2001 [cited 2020 Mar 16];60:876–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11502615. Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, van den Meiracker AH, Vecht CJ, van der Heijde GL, et al. Involvement of the peripheral nervous system in primary Sjögren’s syndrome. Ann Rheum Dis [Internet]. 2001 [cited 2020 Mar 16];60:876–81. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11502615.
119.
go back to reference Sène D, Jallouli M, Lefaucheur J-P, Saadoun D, Costedoat-Chalumeau N, Maisonobe T, et al. Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) [Internet]. 2011 [cited 2019 Dec 16];90:133–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21358442. Sène D, Jallouli M, Lefaucheur J-P, Saadoun D, Costedoat-Chalumeau N, Maisonobe T, et al. Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) [Internet]. 2011 [cited 2019 Dec 16];90:133–8. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21358442.
120.
go back to reference García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81:270–80.CrossRef García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81:270–80.CrossRef
123.
go back to reference Margaretten M. Neurologic manifestations of primary Sjögren syndrome. Rheum. Dis. Clin. North Am. W.B. Saunders; 2017. p. 519–529. Margaretten M. Neurologic manifestations of primary Sjögren syndrome. Rheum. Dis. Clin. North Am. W.B. Saunders; 2017. p. 519–529.
124.
go back to reference • Humă AC, Kecskeş EM, Tulbă D, Bălănescu P, Băicuş C. Immunosuppressive treatment for peripheral neuropathies in Sjogren’s syndrome - a systematic review. Rom J Intern Med [Internet]. 2019; available from: http://www.ncbi.nlm.nih.gov/pubmed/31527298. An excellent systematic review of treatment options in Sjögren’s associated peripheral neuropathy. This review highlights the need for prospective randomized controlled treatment trials for Sjögren’s associated polyneuropathy. • Humă AC, Kecskeş EM, Tulbă D, Bălănescu P, Băicuş C. Immunosuppressive treatment for peripheral neuropathies in Sjogren’s syndrome - a systematic review. Rom J Intern Med [Internet]. 2019; available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​31527298. An excellent systematic review of treatment options in Sjögren’s associated peripheral neuropathy. This review highlights the need for prospective randomized controlled treatment trials for Sjögren’s associated polyneuropathy.
125.
go back to reference Font J, Ramos-Casals M, De la Red G, Pou A, Casanova A, García-Carrasco M, et al. Pure sensory neuropathy in primary Sjögren’s syndrome. Longterm prospective followup and review of the literature. J Rheumatol. 2003;30:1552–7.PubMed Font J, Ramos-Casals M, De la Red G, Pou A, Casanova A, García-Carrasco M, et al. Pure sensory neuropathy in primary Sjögren’s syndrome. Longterm prospective followup and review of the literature. J Rheumatol. 2003;30:1552–7.PubMed
131.
go back to reference Comarmond C, Pagnoux C, Khellaf M, Cordier J-F, Hamidou M, Viallard J-F, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum [Internet]. 2013;65:270–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23044708. Comarmond C, Pagnoux C, Khellaf M, Cordier J-F, Hamidou M, Viallard J-F, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum [Internet]. 2013;65:270–81. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23044708.
134.
go back to reference Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum [Internet]. 2010 [cited 2013 Mar 5];62:616–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20112401. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum [Internet]. 2010 [cited 2013 Mar 5];62:616–26. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20112401.
139.
go back to reference Fanouriakis A, Kougkas N, Vassilopoulos D, Fragouli E, Repa A, Sidiropoulos P. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: case report and review of current clinical evidence. Semin Arthritis Rheum [Internet]. 2015;45:60–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25908179. Fanouriakis A, Kougkas N, Vassilopoulos D, Fragouli E, Repa A, Sidiropoulos P. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: case report and review of current clinical evidence. Semin Arthritis Rheum [Internet]. 2015;45:60–6. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25908179.
142.
143.
go back to reference Collins MP, Dyck PJB, Gronseth GS, Guillevin L, Hadden RDM, Heuss D, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst [Internet]. 2010 [cited 2013 Apr 7];15:176–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21040139. Collins MP, Dyck PJB, Gronseth GS, Guillevin L, Hadden RDM, Heuss D, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst [Internet]. 2010 [cited 2013 Apr 7];15:176–84. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21040139.
146.
go back to reference Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157:1864–8.CrossRef Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157:1864–8.CrossRef
153.
go back to reference • Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med [Internet]. 2017;126:135–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28318820. This retrospective study examined the treatment of sarcoidosis-associated small fiber neuropathy and found that these patients often do not respond to standard treatment (methotrexate and corticosteroids). Rather, they are more likely to respond to IVIg and TNFα inhibitors. • Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med [Internet]. 2017;126:135–8. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28318820. This retrospective study examined the treatment of sarcoidosis-associated small fiber neuropathy and found that these patients often do not respond to standard treatment (methotrexate and corticosteroids). Rather, they are more likely to respond to IVIg and TNFα inhibitors.
154.
go back to reference Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology [Internet]. 2011;76:1758–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21482920. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology [Internet]. 2011;76:1758–65. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21482920.
157.
go back to reference Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758–65. https://doi.org/10.1212/WNL.0b013e3182166ebe . pmid:21482920. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758–65. https://​doi.​org/​10.​1212/​WNL.​0b013e3182166ebe​ . pmid:21482920.
Metadata
Title
Neurologic Manifestations of Systemic Disease: Peripheral Nervous System
Authors
Alex Dworetz, DO
Christina Graley, MD
Hiral Padia, DO
Kelly G. Gwathmey, MD
Publication date
01-08-2020
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 8/2020
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-020-00631-7